NBPNGMHealthcare·Biotechnology#282 in industry

NovaBridge Biosciences

Reports in 17d· 2026-05-14

-38.9% · 90d

$2.43

-0.02 (-0.82%)

After-Hours $2.43(+0.00)

News

(1)

April 2026

Apr 7, 20262 weeks ago20-FHealthcare

NovaBridge Biosciences — 20-F Filing

NBPNovaBridge Biosciences

# 📄 What This Document Is This is NovaBridge Biosciences' **Form 20-F**, their annual report for the year ended December 31, 2025. It’s filed with the U.S. SEC and is required because their shares (as American Depositary Shares, or ADSs) trade on the Nasdaq. Think of it as the company’s comprehensi

Read summaryView on SEC EDGAR

Key Data

Market Cap$281.0M

Open$2.46

Prev Close$2.45

Day Range$2.40 – $2.50

52W Range$0.81 – $6.79

Volume293,353

P/E (TTM)—

EPS$-0.48

Dividend Yield—

Beta1.74

Price Target$8.00(+229.2%)

Next Earnings2026-05-14(17d)

Analyst Ratings

Strong Buy4 analysts

Buy 4Hold 0Sell 0

About

NovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor. The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.

Healthcare · Biotechnology

30 employees

www.novabridge.com